CRK:NYSEComstock Resources, Inc. Analysis
Data as of 2026-06-01 - not real-time
$13.33
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Comstock Resources is trading at $13.33, well below its 20‑day, 50‑day and 200‑day SMAs of 14.80, 17.24 and 19.70 respectively, indicating a pronounced bearish technical backdrop. The RSI of 32.6 suggests the stock is approaching oversold territory, yet the MACD remains in a bearish configuration with the line under the signal. Fundamentally, the company reports a low trailing P/E of 6.0 versus an industry average of 20.5, strong gross (56%) and operating (30%) margins, and a solid ROE of 24%. However, the balance sheet is strained: cash of only $14.8 M against $3.03 B of debt yields a debt‑to‑equity of nearly 99%, and free cash flow is negative $785 M despite positive operating cash flow. Recent Q1 2026 results missed revenue and profit expectations, with non‑GAAP EPS of $0.15 falling 34% short of consensus, and the stock fell on the news.
The valuation gap is sizable, with a DCF‑derived fair value of $46.58 and analyst median target of $18, implying roughly 30% upside from current levels. While the extreme greed sentiment (Fear‑Greed Index 93) reflects market optimism, the high 30‑day volatility (≈60%) and significant historical drawdown (‑57%) heighten risk. Given the cheap valuation, strong margins, and long‑term upside potential, the stock may be attractive for patient investors, but short‑term pressure from technical weakness and debt concerns warrants caution.
The valuation gap is sizable, with a DCF‑derived fair value of $46.58 and analyst median target of $18, implying roughly 30% upside from current levels. While the extreme greed sentiment (Fear‑Greed Index 93) reflects market optimism, the high 30‑day volatility (≈60%) and significant historical drawdown (‑57%) heighten risk. Given the cheap valuation, strong margins, and long‑term upside potential, the stock may be attractive for patient investors, but short‑term pressure from technical weakness and debt concerns warrants caution.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below all major SMAs and key support
- Q1 earnings miss and profit below consensus
- High leverage with debt‑to‑equity near 100%
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Significant valuation upside to analyst targets
- Strong operating margins and ROE
- Continued debt burden and negative free cash flow
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Low P/E relative to industry and high margin profile
- DCF fair value indicating substantial upside
- Potential for debt reduction and cash flow improvement over time
Key Metrics & Analysis
Financial Health
Revenue Growth14.20%
Profit Margin31.20%
P/E Ratio6.0
ROE24.24%
ROA3.62%
Debt/Equity98.70
P/B Ratio1.4
Op. Cash Flow$996.8M
Free Cash Flow$-785633472
Industry P/E20.5
Technical Analysis
TrendBearish
RSI32.6
Support$12.84
Resistance$17.79
MA 20$14.80
MA 50$17.24
MA 200$19.70
MACDBearish
VolumeStable
Fear & Greed Index93.25
Valuation
Fair Value$46.58
Target Price$17.50
Upside/Downside31.28%
GradeUndervalued
TypeBlend
Risk Assessment
Beta-0.18
Volatility60.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
ZIONP
Zions Bancorporation N.A. - Depositary Shares each representing a 1/40th ownership interest in a share of Series A Floating-Rate Non-Cumulative Perpetual Prefer
STOCKZION
Zions Bancorporation N.A.
STOCKYOU
Clear Secure, Inc.
STOCKABCL
AbCellera Biologics Inc.
STOCKWETH
Wetouch Technology Inc.
STOCKSOPA
Society Pass Incorporated
STOCKThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.